SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.
Follow SABS
SAB Biotherapeutics, Inc. (SABS) EV/Sales
As of 16 October 2026, SAB Biotherapeutics, Inc. (SABS) trades at a EV/Sales of 62.8×. Over the past ten years it has ranged from −53.2× (October 2025) to 133× (July 2026); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 10.8× | — |
| FY2023 | −6.5× | — |
| FY2022 | 0.7× | (75.04%) |
| FY2021 | 2.9× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 10.8× | — |
| Jun 2024 | −2.1× | — |
| Mar 2024 | −0.4× | — |
| Dec 2023 | −6.5× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −8.3× |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| FATE Fate Therapeutics, Inc. compare | 13.1× |
| ACIU AC Immune compare | 31.3× |
| SABS SAB Biotherapeutics, Inc. | 62.8× |
| SLGL Sol-Gel Technologies Ltd. compare | 127× |
| IMRX Immuneering Corporation compare | 260× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)